Earnings Call Intelligence Subscribe
Home › Call Sheets › DXCM › Q3'26
Call sheet · Q3'26

DexCom (DXCM)

Q3'26 earnings call · held October 29, 2026 · compared with the Q2'26 call · management-credibility review
8/12
Disclosure score
4 medium, 5 low flags
Financial quality
Bottom line
The sleeper story is international: revenue was literally flat sequentially at $375M while growth cratered from 19%/16% organic to 5%/5%, and management's one-line 'lapping comps' explanation deserves more scrutiny than it got on this call. The obvious headline, an 11% revenue beat with 380bps of gross margin expansion and raised guidance, is real, but it's being driven almost entirely by U.S. share gains (+14%) while the international and retention stories go quiet. The binding constraint right now isn't demand, it's payer architecture: the CVS exclusion, quantified at 'less than 4% of U.S. revenue', is small in isolation but management's own words, 'it goes up by a pretty significant amount... much, much, much higher than that', confirm the economics of losing preferred status are brutal, and they wouldn't quantify how many other contracts carry that exposure. My view changes if international organic growth doesn't snap back above 15% by Q1 2027 as promised, or if management is forced to disclose an actual retention percentage rather than the word 'stable'.

The 30-second version

  • International just went from rocket fuel to flat line, and nobody asked why in real-time
  • Beat-and-raise headline masks a payer contract loss management is sizing but not fully derisking
  • Retention/utilization, the metric that matters most as the funnel widens into Type 2 NIT, has no number attached to it anymore

What changed this quarter

MetricQ2'26Q3'26Change
Total Revenue$1.31B, +13% YoY / +12% organic$1.34B, +11% YoY / +11% organicGrowth decelerated 200bps YoY, 100bps organic
U.S. Revenue$933M, +11% YoY$970M, +14% YoY+300bps acceleration, best U.S. print of the year
International Revenue$375M, +19% reported / +16% organic$375M, +5% reported / +5% organicFlat sequential dollars; growth cut by two-thirds
Gross Margin64.1%65.1%+100bps QoQ, +380bps YoY, highest since Q4'22
Operating Income / Margin$328.3M / 25.1%$339.5M / 25.3%Modest leverage despite Ireland startup drag
Adjusted EBITDA / Margin$421.3M / 32.2%$435.2M / 32.4%Steady expansion
Net Income / EPS$269.1M / $0.70$275M / $0.73+4% EPS growth
Cash & Equivalents$1.9B$1.8BDeclined on buyback execution, not operations
Free Cash Flow (cumulative)$600M through H1'26$900M through 9 monthsImplies ~$300M Q3 FCF, consistent run-rate
Buyback Program$1B committed for 2026, $600M executed in Q2$1B goal already fully executed; new $1B authorization for 2027Full-year target hit early, doubling down

Accountability tracked

7 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full DXCM Q3'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.